Compare IDYA & NVG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IDYA | NVG |
|---|---|---|
| Founded | 2015 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.7B |
| IPO Year | 2019 | N/A |
| Metric | IDYA | NVG |
|---|---|---|
| Price | $31.40 | $11.99 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 16 | 0 |
| Target Price | ★ $51.21 | N/A |
| AVG Volume (30 Days) | ★ 824.6K | 641.4K |
| Earning Date | 05-05-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 4.65% |
| EPS Growth | ★ 61.90 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $218,710,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $191.08 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 3024.43 | N/A |
| 52 Week Low | $13.45 | $11.00 |
| 52 Week High | $39.28 | $13.59 |
| Indicator | IDYA | NVG |
|---|---|---|
| Relative Strength Index (RSI) | 44.31 | 22.42 |
| Support Level | $29.15 | $11.51 |
| Resistance Level | $35.47 | $12.51 |
| Average True Range (ATR) | 1.47 | 0.14 |
| MACD | -0.26 | -0.08 |
| Stochastic Oscillator | 30.38 | 4.36 |
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
Nuveen AMT-Free Municipal Credit Income Fund is a diversified, closed-end management investment company. Its objective is to provide current income exempt from regular federal income tax and federal alternative minimum tax applicable to individuals and enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the investment adviser believes are underrated or undervalued or represent undervalued municipal market sectors.